Was Mylan The First To Set Its Sights On Ranbaxy?
This article was originally published in PharmAsia News
Way before Sun Pharma swooped in to buy Ranbaxy, industry experts say Mylan may have taken a close look at buying the company. Although the world’s fourth-largest drug maker pulled out initially, sources say negotiations may still be revolving around sourcing raw materials for esomeprazole, an exclusive drug launch opportunity that could brighten Ranbaxy’s U.S. fortunes.
You may also be interested in...
Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.